Description
Ostarine (MK-2866) 10 mg Driada Medical — ostarine (MK-2866) from Driada Medical at 10 mg. Selective androgen receptor modulator — tissue-targeted for muscle and bone. Milder HPTA suppression than anabolic steroids.
Key Benefits
- Most-studied SARM — extensive clinical trial data
- Low suppression at 10–15 mg/day — recovery often possible without PCT
- Cutting recomp compound — lean mass in caloric deficit
- Oral once-daily dosing
- Starting compound for SARM-curious users
- Each unit dosed at 10 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 10–25 mg/day for 8 weeks. Women 5–10 mg/day. Single daily dose adequate given long half-life. Cycles 8–12 weeks. Doses above 25 mg/day suppression becomes meaningful.
How It Works
MK-2866, selective androgen receptor modulator. Binds the AR with tissue selectivity: high activity in muscle and bone, low activity in prostate and skin. Downstream anabolic effects without the full androgenic profile of AAS.
Pharmacokinetics
Plasma half-life approximately 24 hours. Once-daily dosing sufficient. Steady-state in 5 days.
Cycle & Stacking Guide
Beginner SARM cycle: 10–15 mg/day × 8 weeks. Mild mini-PCT (Nolva 20 mg/day × 4 weeks) if bloodwork confirms suppression. Stacks with cardarine for recomp or with TRT for lean gains.
Manufacturer Notes
Driada Medical positions itself at the affordable end of the market while maintaining third-party lab verification. Their vial caps carry a tamper-seal date code.
Storage & Handling
Store in the original blister or bottle at 15–25 °C, away from direct sunlight, heat, and humidity. Oral preparations lose potency faster if exposed to moisture; keep the desiccant (if included) with the tablets. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.